In vivo and ex vivo expansion of hematopoietic stem cells with a targeted combination of clinically tested, FDA approved drugs
US9050315B2 · kind B2 · utility
1Cited by
0References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 11, 2011 |
| Grant date | Jun 9, 2015 |
| Priority date | — |
| Expiry date | Jan 29, 2032 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides a therapeutic approach to maintain and expand HSCs in vivo using currently available medications that target GSK-3 and mTOR. The present invention also provides a system and method for the ex vivo culturing of HSCs, where an mTOR inhibitor is combined with a GSK-3 inhibitor within the culturing conditions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.